Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01333423
Recruitment Status : Withdrawn
First Posted : April 12, 2011
Last Update Posted : June 26, 2012
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : September 2015
Study Completion Date : No date given